Chorioretinal Vascular Disease
Ophthalmology
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
RegeneronIntravitreal Aflibercept Injection
AmgenABP 938
AmgenABP 938
Clinical Trials (3)
Total enrollment: 690 patients across 3 trials
Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe
Start: Dec 2018Est. completion: Aug 202065 patients
Phase 4Completed
A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)
Start: Jan 2023Est. completion: Mar 202349 patients
Phase 3Completed
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
Start: Jun 2020Est. completion: Jan 2023576 patients
Phase 3Completed
Related Jobs in Ophthalmology
Lead Data Manager
Genomics
Remote
10h ago
Cleanroom and Laboratory Technician
SAB BIO
10h ago
Material Handler - 8 Hour Day Shift
Pfizer
United States - Kansas - McPherson
Yesterday
Senior Process Technician - Rotating 2nd Shift
Pfizer
United States - Massachusetts - Andover
Yesterday
$27 - $45/hr
Staff Equipment and Systems Engineer
Johnson & Johnson
Plymouth, Minnesota, United States of America
Yesterday
$94K - $152K/yr
APAC Regulatory Affairs Manager
Johnson & Johnson
Singapore, Singapore
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space